Nasdaq GlobeNewswire

First Medical Patent Issued for the Oculenz(TM) Augmented Reality Glasses

Del

Ocutrx(TM) AR Glasses Garners First Medical Patent for Restoring Functional Sight to Patients with Visual Field Deficits

IRVINE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California based Augmented Reality (AR) Glasses developer today announced that the company's core AR medical application technology has been issued its first patent by the United States Patent and Trademark Office (USPTO). The company's Augmented Reality headset, called Oculenz(TM) boasts the widest field-of-vision in the industry, with a 110-degree high-resolution heads-up display, in a wirelessly connected, untethered, micro-weight headset.  The patent also teaches how the Oculenz ARwear(TM) can work in conjunction with smart contact lenses as the display and eye-tracking. 

"This first patent award validates our core technology for using our AR platform innovations for medical applications," stated Michael H. Freeman, CEO/CTO and Founder of Ocutrx. "This is a real milestone for creating value for Ocutrx's patent portfolio and an incredible step forward in securing patent rights around the world," Freeman said. "We immediately filed a Continuation Patent to focus on the previously filed specification elements incorporating eye-tracking with an AR head mounted display for the larger AR market."  

The company plans to also market their Oculenz to other sectors including gaming, commercial, industrial, HAZMAT, e-commerce, aerospace, drones and defense.  "While many AR companies built a platform first, and are now looking to find a market," said Scott Evans, M.B.A., Ocutrx COO, "we strategically designed our first ARwear for the medical industry, where there are many highly-motivated buyers, then we intent to expand into the AR market-at-large." 

Ocutrx was founded in 2015 by Michael H. Freeman, an Emmy Award-winning designer of streaming mobile video technology which became the basis for the IEEE 802.11(n) MIMO standard.  Freeman created the first streaming smart-phone video product which was licensed by virtually all of the cell companies which existed in the 1990's.  The streaming video technology and patents were later sold to Samsung Electronics. 

"The Oculenz is the first ground-breaking technology to offer a solution for advanced central visual defects in patients with retinal disease," said Dr. Thomas Finley, M.D. a Vitreoretinal surgeon and member of the Ocutrx International Medical Advisory Board (IMAB). "This innovative AR device brings a new hope to regain functional vision previously considered impossible. The impact on the individual's quality of life and retained or regained ability to productively function at home and in the workplace will be immeasurable."

The USPTO determined that Ocutrx's first patent application was allowable covering a diagnostic phase where the patients can wear the Oculenz to map their own retinal defects, alone or with the help of their physicians, and a second corresponding display phase where the video is buffered according to the retinal map and displayed over the patient's real-world vision. The Oculenz's buffered display shows all the real-world video image, but none is shown on the exact area of the patient's eye defect.  Instead, it is directed to the patient's existing good areas of the macula or near adjacent peripheral retina.

"The Oculenz technology works somewhat like how we all have a natural blind spot in our vision that we do not realize on a day to day basis," said Dr. Lars Freisberg, M.D., an international Retinal Specialist surgeon, licensed in the U.S., Norway and Germany, and member of the Ocutrx IMAB. "However, you never really see this hole," explained Dr. Freisberg, "because the brain fills it in with other gathered visual information."   

"With the Oculenz the idea is that the patient senses the entire image and learns to disregard the defect area through 'neural adaptation' due to the 'plasticity of the brain,'" said Dr. R. Wade Crow, M.D., Neural Ophthalmologist and Assistant Professor of Neuro-Ophthalmology at the University of California-Irvine and member of the Ocutrx IMAB. "Working with visual input, the brain can train itself to not see redundant or unnecessary things."

About  Ocutr x

With corporate headquarters in the OC at Irvine, California, and a research and R&D lab in the Midwest, located in Oklahoma, Ocutrx is a new breed of AR manufacturing company focusing on the lightest weight headset with the largest field-of-vision in the market. At a time when worldwide applications for easy-to-wear and easy-to-use AR solutions are being touted as the "next big thing after the smartphone" Ocutrx is creating impactful, revolutionary "AR glasses for the masses"(TM).   

To learn more about Ocutrx, please visit the company website at www.ocutrxarwear.com.

Media Contact: 
Karen Clarke
Media Representative
Ocutrx Vision Technologies, LLC
karen.clarke@ocutrxarwear.com
(949) 623-8408

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/03bd1b8e-4d74-4836-b372-a1aa0f110ddd http://www.globenewswire.com/NewsRoom/AttachmentNg/6eeb0bdf-925b-48e8-995c-589429b422f2




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ocutrx Vision Technologies, LLC via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

TESARO Announces Data Presentations at ESMO 2018 Congress20.10.2018 07:30Pressemelding

Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019 MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high (MSI-H) endometrial cancer presented during the European Society for Medical Oncology (ESMO) Congress. Blinded, pooled interim safety data from the Phase 3 PRIMA trial of niraparib in patients with first-line ovarian cancer regardless of biomarker status were also presented in a poster discussion session and additional data from the QUADRA trial of niraparib for treatment of late-li

The Navigators Group, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger19.10.2018 22:01Pressemelding

STAMFORD, Conn., Oct. 19, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) (“Navigators” or the “Company”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with its previously announced merger with a direct wholly owned subsidiary (“Merger Sub”) of The Hartford Financial Services Group, Inc. (“The Hartford”), expired at 11:59 p.m. Eastern Time on October 18, 2018. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the merger, which remains subject to other closing conditions in the Agreement and Plan of Merger, dated as of August 22, 2018, by and among the Company, The Hartford and Merger Sub. About Navigators The Navigators Group, Inc. (NASDAQ: NAVG) (“Navigators” or the “Company”) is a global specialty insurance holding company. We provide customized insurance solutions designed to protect clients from the complex risk

ATTO Technology introduces the XstreamCORE® FC 7600 32Gb Fibre Channel to 12Gb SAS Hardware Accelerated Storage Controller19.10.2018 15:00Pressemelding

AMHERST, N.Y., Oct. 19, 2018 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for 30 years, announces availability of the ATTO XstreamCORE® FC 7600 storage controller. ATTO XstreamCORE FC 7600 is a standalone, accelerated storage controller that connects any external SAS device, such as a JBOD of HDDs or SSDs, a RAID array or external tape devices, and presents them isolated to individual hosts or shared over a Fibre Channel SAN fabric. It includes ATTO exclusive technologies, ATTO xCORE hardware acceleration processor and ATTO intelligent Bridging Architecture™, that combine to keep latency astonishingly low at three microseconds. For less than the price of a performance server, XstreamCORE FC 7600 enables up to 64 Fibre Channel connected clients to remotely access and share up to 240 SAS/SATA SSD or HDD devices via JBOD or JBOF at direct attached speeds with consistent, d

Biome Grow Introduces PEI Brand, Red Sands Craft Cannabis Co.19.10.2018 13:30Pressemelding

TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (FSE:6OTA) is pleased to introduce its fifth subsidiary company and brand, Red Sands Craft Cannabis Co. (“Red Sands”). Red Sands is located in Prince Edward Island (PEI) and will service both the local and tourist markets in that province with locally produced and regionally grown cannabis products. The Red Sands Craft Cannabis Co. brand reflects PEI’s iconic red sand beaches and the craft goods and services that are produced locally. Visually, it balances the vibrant, energetic colours with the calm nature that PEI is known for, setting the stage for the tailored cannabis products that Red Sands will offer. Though the smallest Canadian province both in terms of land area and population, with approximately 153,000 residents living on the Island, the province has a robust tourism industry. In 2017, the province set records with more than 1,000,000 overnight stays, by an estimated 1.56 million

CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35Pressemelding

DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.

Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21Pressemelding

BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom